Emily Aman, MPH, from the University of Rochester Medical Center

Rachel White, from the University of Rochester Medical Center

 Caregiver Perceptions Highlight Gaps in Pediatric Asthma Specialist Access

Fewer than 2 in 10 children with poorly controlled asthma in marginalized communities had seen a pulmonologist or allergist in the prior year, a new study showed.

This sub-analysis of the TEAM-UP trial illustrates a disconnect between guideline recommendations and real-world care. Although caregiver support for specialty care was high—81% reported believing that a specialist visit would benefit their child—structural, communication, and referral barriers limited actual access.

“I think the overall perception…is positive,” investigator Emily Aman, MPH, from the University of Rochester Medical Center, told HCPLive. “Maybe [there’s] some medical mistrust, [but] I think overall, they're receptive to this specialized care. We just need to figure out how to remove some of the barriers that exist.”

Among 325 children aged 4 to 12 years from Rochester, New York, 37% had ever seen an asthma specialist, and 16% had seen one in the past year. The cohort was predominantly publicly insured (80%), with 58% identifying as Black and 35% as Hispanic. Black children accounted for only 39% of those who had ever received specialty care, highlighting racial disparities.

Children from households with annual incomes ≥$35,000, caregivers with higher education levels, and married or partnered caregivers were more likely to access specialty care. Comorbidities and environmental exposures, including allergic rhinitis (38%) and household smoke exposure (42%), were prevalent across the cohort, indicating that all children met referral thresholds regardless of risk factors.

The study ultimately demonstrated that caregiver receptiveness is high and primary care provider referrals are critical, despite only 23% of caregivers reporting receiving a referral.

“This all points to the need for a multi-faceted approach to reducing barriers using things like telemedicine, which you know is being used for many health conditions for children, including asthma,” said investigator Rachel White, also from the University of Rochester Medical Center.

White continued by talking about how telemedicine can reduce transportation barriers. Some explained that some regions have mobile clinics to combat these transportation barriers.

“We're actually working on a project right now that's partnering with school nurses to make specialist care and asthma care in general more accessible to school-age kids,” White said. “Building those partnerships with school health staff and providers is also very important.”

Aman E, White RN, Stern J, et al. Pediatric asthma specialist care utilization among marginalized children with poorly controlled asthma. 

. 2026;63(2):198-205. doi:10.1080/02770903.2025.2581016

Aman E and White R. Most Marginalized Children with Uncontrolled Asthma Miss Specialist Care. HCPLive. Published on February 7, 2026. Accessed on February 10, 2026. https://www.hcplive.com/view/most-marginalized-children-uncontrolled-asthma-miss-specialist-care

Videos

In an interview with HCPLive, Emily Aman, MPH, and Rachel White, share that most marginalized children with uncontrolled asthma miss specialist visits despite caregiver support due to existing barriers.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Caregiver Perceptions Highlight Gaps in Pediatric Asthma Specialist Access

Adam Bress, PharmD, MS, is a professor of the department of population health sciences at the University of Utah School of Medicine and director of the Integrating Medicine & Policy to Achieve Healthcare Transformation (IMPACT HSR) program.

Apple Watch Hypertension Notifications May Give False Reassurance, With Adam Bress, PharmD, MS

 notification feature can successfully identify adults with undiagnosed hypertension, recent data highlights its capacity for misclassification.

The notification feature, which uses photoplethysmography signals to inform users of possible hypertension without a blood pressure cuff, was cleared by the 

 in September 2025. A subsequent validation study comparing the feature to home blood pressure monitoring over 30 days saw 41.2% of patients with undiagnosed hypertension receive an alert versus 58.8% who did not. Among those without hypertension, 92.3% did not receive an alert, while 7.7% received an inaccurate alert.

“The trustworthiness of a positive test is higher in groups that have a higher prevalence of undiagnosed hypertension,” Adam Bress, PharmD, MS, professor of the department of population health sciences at the University of Utah School of Medicine and director of the Integrating Medicine & Policy to Achieve Healthcare Transformation (IMPACT HSR) program, told 

 in an exclusive interview. “The opposite is true with the trustworthiness of a negative test. The risk there is the idea of being falsely reassured that you don’t have hypertension.”

The current study, conducted by Bress and colleagues, incorporated data from the National Health and Nutrition Examination Survey (NHANES) 2017-2020. Patient eligibility was determined based on the intended use population: patients were included if they were non-pregnant, aged ≥22 years, unaware of having hypertension, and not actively taking antihypertensive medication.

Prevalence of undiagnosed hypertension was estimated in the overall population and select subgroups. Bress and colleagues applied test performance metrics to estimate the percentage of true-positive, false-negative, true-negative, and false-positive results, as well as positive and negative likelihood ratios, positive and negative predictive values, and posttest probabilities.

A total of 3983 participants were enrolled in the study, representing 127 million US adults. With the estimated prevalence of hypertension in the overall population, the positive predictive value was 69.1% (95% CI, 63.3-74.9%), while the negative predictive value was 79% (95% CI, 76.6-81.3%).

Analysis was also conducted across subgroups – for example, alerts in patients <30 years increased the probability of hypertension from 0.14 (95% CI, 0.11-0.17) to 0.47 (95% CI, 0.39-0.56), while the absence of an alert lowered the probability to 0.1 (95% CI, 0.07-0.12). However, among patients ≥60 years, an alert raises the probability from 0.45 (95% CI, 0.39-0.5) to 0.81 (95% CI, 0.76-0.86), and the absence thereof lowers it to 0.34 (95% CI, 0.29-0.39).

Bress and colleagues emphasize the Apple Watch’s explicit statement that the notification feature is not intended to diagnose hypertension – instead, it is designed to prompt users to seek clinical evaluation. However, false reassurance may mislead or discourage individuals from undergoing appropriate screening, ultimately resulting in missed opportunities for early detection and treatment. If future cuffless devices are to contribute to hypertension detection, Bress and colleagues state that rigorous validation and thoughtful integration into population screening will be needed.

“Clinical inertia is one of the leading causes of why blood pressure control rates are not as good as they could be,” Bress said. “The Apple Watch hypertension notification feature is only designed for people without a diagnosis of hypertension, so it’s not intended or designed for treatment and monitoring of people on antihypertensive medications. However, tools like wearables or home blood pressure monitors to help reduce clinical inertia are very important and are currently under study to hopefully add to the clinician’s toolkit.”

Editor’s Note: Bress reports disclosures with the National Institute on Aging, the National Heart, Lung, and Blood Institute, and Alnylam.

Cohen JB, Addo DK, Jacobs JA, et al. Impact of a smartwatch hypertension notification feature for Population Screening. JAMA. Published online February 9, 2026. 

Browning SC, Assistant Director, Division of Cardiac Electrophysiology, US Food and Drug Administration, to Bonnie Wu, Apple Inc, September 12, 2025, Summary for Apple Hypertension Notification Feature (K250507). Accessed September 15, 2025. 

https://www.accessdata.fda.gov/cdrh_docs/pdf25/K250507.pdf

Bress highlights the potential shortcomings of relying on the Apple Watch as a diagnostic tool for hypertension, discussing its potential for false negatives.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Jonggi Choi, MD, PhD, is an associate professor at Asan Medical Center, University of Ulsan College of Medicine, and visiting scholar at Mass General Hospital.

Statins and Improved Long-Term Liver Outcomes in PBC, With Jonggi Choi, MD, PhD

Statins are widely recognized as cholesterol-lowering agents, but over the past decade, accumulating evidence has suggested their benefits may extend beyond lipid management.

 highlights a reduced risk of hepatic decompensation and major liver events in patients with primary biliary cholangitis (PBC) taking statins, supporting a potential protective effect in this population.

“Several large observational studies have suggested that statins may slow liver fibrosis, reduce complications related to portal hypertension, and even lower the risk of liver cancer,” Jonggi Choi, MD, PhD, an associate professor at Asan Medical Center, University of Ulsan College of Medicine, and visiting scholar at Mass General Hospital, told HCPLive. “About a year ago, our group also published a large case study in 

 showing that statin use was associated with improved outcomes in patients with overall chronic liver disease, which further raised interest in their potential liver protective effects. However, when it comes to PBC, the evidence has been much more limited.”

He noted that PBC is a rare autoimmune cholestatic liver disease characterized by chronic inflammation and progressive destruction of the small bile ducts, ultimately leading to cirrhosis if left untreated. Most prior studies in PBC, he explained, focused on short-term laboratory changes rather than clinically meaningful long-term outcomes like liver failure, transplantation, or cancer. As a result, whether statins influence the long-term course of PBC has remained unclear.

Because randomized controlled trials are particularly challenging in rare diseases like PBC, investigators used a target trial emulation approach with real-world data. As Choi described, this method structures observational data to closely mimic a randomized clinical trial, helping to minimize common biases such as immortal time bias.

Using 2 large, independent electronic health record databases from Mass General Brigham and Asan Medical Center, investigators identified statin initiation on a month-by-month basis. In each monthly trial, statin initiators were matched in a 1:2 ratio to non-users using propensity score matching.

The primary outcome was hepatic decompensation while the secondary outcome was a composite major adverse liver outcome (MALO), including decompensation, hepatocellular carcinoma, and liver transplantation.

Among 2889 eligible patients, 443 statin users were matched to 886 non-users. During a median follow-up of 3.8 years, hepatic decompensation occurred in 24 statin users (5.4%) and in 67 non-users (7.6%) (hazard ratio [HR], 0.61; 95% confidence interval [CI]: 0.38–0.97). Statin use was additionally associated with a reduced risk of MALO (HR, 0.58; 95% CI: 0.38–0.89).

Importantly, Choi noted sensitivity analyses stratified by data source (MGB, HR 0.65; AMC, HR 0.60) and cirrhosis status (HR 0.70 for cirrhosis; HR 0.57 for without) showed similar directional trends, indicating that results were consistent across different groups.

Editors’ Note: Choi reports relevant disclosures with Gilead.

Choi J, Xu J, Nguyen VH, et al. Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study. 

Choi J, Nguyen VH, Przybyszewski E, et al. Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver Disease. 

 2025;185(5):522–530. doi:10.1001/jamainternmed.2025.0115

Choi describes existing evidence on statin use in patients with liver disease and reviews his new research about their potential utility in PBC.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Positive results have been released from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in individuals with 

These data, announced on February 10 by Nektar Therapeutics, resulted from the global, phase 2b REZOLVE-AD study, involving 393 individuals with atopic dermatitis. Atopic dermatitis is known to impact around 30 million patients in the US. The 

 granted a Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients aged 12 years and older with atopic dermatitis.

"These data show that rezpegaldesleukin, as a broad-based Treg agonist, is emerging as one of the most important mechanisms in development to treat atopic dermatitis," Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at The George Washington University School of Medicine and Health Sciences, said in a statement.

 "With both monthly and quarterly maintenance dosing, new and sustained responses were observed across the key endpoints of EASI-75, vIGA-0/1 and itch and with a large proportion of patients achieving complete clearance with EASI-100."

Investigators of the REZOLVE-AD study began in October 2023, conducting their research at roughly 110 sites around the world. Most of the participants involved in this analysis were treated in Europe (68%), followed by the US (16%), Canada (11%), and Australia (5%). Patients were required, in order to qualify for involvement, to have an Eczema Area and Severity Index (EASI) score of 16.0 at minimum, a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 3 or higher at both screening and randomization, and a level of body surface area involvement of 10% or greater.

There were 393 subjects involved in this global phase 2b study, with participants being randomized during the 16-week induction phase in a 3:3:3:2 ratio to be provided with 1 of 3 subcutaneous doses of rezpegaldesleukin or placebo. Rezpegaldesleukin-treated individuals who attained at least a 50% reduction in their 16-week EASI scores were re-randomized on a 1:1 basis to continue with the drug at their original induction dose administered either every 4 or every 12 weeks through Week 52 as part of a blinded maintenance period.

Those shown not to meet the EASI-50 threshold during induction entered a treatment escape arm that allowed up to 36 additional weeks of use. Both of the aforementioned maintenance schedules were linked with durable disease control. This was across multiple efficacy measures, including EASI-75, EASI-90, vIGA-AD response, and improvement on the Itch Numerical Rating Scale. The 24 µg/kg dose administered either monthly or quarterly demonstrated the strongest response maintenance by the 52-week mark.

Notably, continued treatment led to additional clinical gains, with a substantial number of patients achieving new EASI-75, EASI-90, itch, and vIGA-AD 0/1 responses by the end of the study, despite less frequent dosing. In the maintenance phase, the proportion of patients reaching complete skin clearance increased markedly. Among all re-randomized participants, EASI-100 response rates rose from 4% to 22% with Q4W dosing and from 9% to 18% with Q12W dosing between weeks 16 and 52.

Among those who already had an EASI-75 or vIGA-AD response at maintenance baseline, EASI-100 rates were found to have risen from 6% to 30% with monthly dosing and from 14% - 27% with quarterly dosing regimens. The team highlighted these rates as representing a 2- to 5-fold improvement in complete response rates for the 24 µg/kg regimens. The safety profile of rezpegaldesleukin during maintenance was consistent with earlier data from the induction period, with the investigators finding no new safety signals. Across all of those assessed, discontinuations resulting from AEs occurred in 3.5%.

Reports of treatment-emergent adverse events (TEAEs) were noted among 72% of re-randomized rezpegaldesleukin-treated individuals, 65% of placebo-treated patients in maintenance, and 83% of subjects in the escape cohort. Reactions at patients’ injection sites were the most often AEs reported, the majority of which were mild, occurred less frequently than during induction, and resulted in discontinuation of the drug in only .7% of those evaluated.

"These data highlight that rezpegaldesleukin offers a completely novel therapeutic modality for the potential treatment of atopic dermatitis with numerous advantages to existing classes," said David Rosmarin MC, the chair of the department of dermatology and associate professor of Dermatology at Indiana University School of Medicine, said in a statement.

New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing. Nektar Therapeutics. February 10, 2026. 

https://ir.nektar.com/news-releases/news-release-details/new-rezolve-ad-maintenance-data-atopic-dermatitis-demonstrate

Smith T. FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis. HCPLive. February 10, 2025. Accessed February 10, 2026. 

https://www.hcplive.com/view/fda-grants-fast-track-designation-rezpegaldesleukin-atopic-dermatitis

Articles

Rezpegaldesleukin, a Treg agonist biologic, demonstrated durable and incremental efficacy through 52 weeks in moderate-to-severe atopic dermatitis following a 16-week induction and blinded maintenance period. Patients achieving EASI-50 at Week 16 maintained control with Q4W or Q12W dosing, with the 24 µg/kg regimen showing the strongest maintenance. Complete clearance improved substantially during maintenance, with EASI-100 rising from single digits at Week 16 to ~18%–22% by Week 52. Safety remained consistent, without new signals.

These data highlight the impact of rezpegaldesleukin therapy on adults with moderate-to-severe atopic dermatitis in the phase 2b REZOLVE-AD study.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Takeda announced on February 10, 2026, that the US Food & Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review of oveporexton (TAK-861) for the treatment of 

Oveporexton, an investigational oral orexin receptor (OX2R)-selective agonist, addresses the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA assigned oveporexton a Prescription Drug User Fee Act (PDUFA) target date in the third quarter of 2026.

“The FDA’s acceptance of our NDA is a milestone for people living with narcolepsy type 1,” said Andy Plump, MD, PhD, president of R&D at Takeda, in a statement. “Considering the high unmet need, this community deserves a new and different treatment approach that aims to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling.

Patients with NT1 experience a spectrum of physical, cognitive, and psychosocial effects. Despite available treatments, most patients with this rare neurological disease continue to live with these debilitating symptoms.

The NDA is supported by pivotal phase 3 data from FirstLight and (TAK-861-3001) and RadiantLight (TAK-861-3002). Takeda had presented this phase 3 data at World Sleep 2025 in Singapore on September 8, 2026. Both FirstLight and RadiantLight met all primary and secondary endpoints.

These trials demonstrated significant and clinically meaningful improvements in wakefulness, excessive daytime sleepiness, cataplexy, ability to maintain attention, overall quality of life, and daily functions by week 12 with either 1 mg or 2 mg of oveporexton taken twice daily (all 

 By the end of the trial, symptom levels were all near normal ranges.

The trial showed that most patients treated with oveporexton 2 mg twice a day achieved wakefulness within a normal range (≥ 20 minutes) on the Maintenance of Wakefulness Test, and nearly 85% of patients reached Epworth Sleepiness Scale scores that were comparable to healthy controls (≤ 10). Regarding cataplexy, participants had a median percent change from baseline of > 80%. Compared to placebo, the average cataplexy-free days improved from 0 days at baseline to 4 – 5 days per week at week 12.

Furthermore, oveporexton demonstrated statistically significant changes from baseline in the narcolepsy severity score compared to placebo. More than 70% of participants reported the lowest severity levels (0 – 14). Additionally, 97% of participants treated with oveporexton reported improvements, as reflected by the self-related Patient Global Impression of Change (PGI-C) scale.

Oveporexton significantly improved quality of life, as seen through the Short Form-36-item (SF-36) survey. Patients also experienced improvements in the EuroQol 5-Dimension 5-Level (EQ-5D-5L).

The treatment was generally well-tolerated; common adverse events included insomnia, urinary urgency, and urinary frequency. No serious treatment-related adverse events were reported.

The FDA had previously granted oveporexton Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in NT1. Oveporexton had also received a Breakthrough Therapy designation from the Center for Drug Evaluation of China’s National Medical Products Administration, as well as a Sakigake designation from the Japanese Ministry of Health, Labor, and Welfare.

“We are one step closer to potentially transforming the current treatment paradigm and intend to deliver through our leading work in orexin science,” Plump continued.

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1. Takeda. Published on February 10, 2026. Accessed on February 10, 2026. 

https://www.takeda.com/newsroom/newsreleases/2026/fda-accepts-nda-priority-review-oveporexton-narcolepsy-type-1/ 

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025. Takeda. Published on September 8, 2025. Accessed on February 10, 2026. 

https://www.takeda.com/newsroom/newsreleases/2025/takeda-orexin-data-oveporexton-phase-3-narcolepsy-world-sleep-2025/

FDA grants Priority Review for Takeda’s oveporexton, an oral orexin agonist for narcolepsy type 1, showing near-normal symptom control in phase 3.

FDA News

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

FDA Accepts NDA, Grants Priority Review for Oveporexton to Treat Narcolepsy Type 1

In their closing remarks, Auchus and DeFronzo emphasize routine screening of high-risk patients, the persistent cardiovascular burden of hypercortisolism despite risk-factor treatment, and the necessity of targeting cortisol excess itself.

Video Series

Special Reports

Final Takeaways: Screening, Cardiovascular Risk, and Treating Cortisol as the Root Cause

Auchus and DeFronzo survey the broader pharmacologic armamentarium for Cushing syndrome and hypercortisolism, including metyrapone, osilodrostat, ketoconazole, levoketoconazole, pasireotide, and investigational agents such as relacorilant and ACTH receptor antagonists.

Beyond Mifepristone: Enzyme Inhibitors, Pituitary-targeted Agents, and Emerging Therapies

DeFronzo and Auchus underscore the magnitude of metabolic benefit with mifepristone, the complexity of managing withdrawal and electrolyte issues, and the importance of specialist support and education for primary care physicians.

Practical Use of Mifepristone and the Need for Endocrinology–Primary Care Collaboration

Auchus and DeFronzo review mifepristone (RU-486) as a glucocorticoid receptor antagonist for Cushing syndrome and refractory hypercortisolism, detailing its effects on glycemic control, weight, and safety considerations from the SEISMIC and CATALYST trials.

Mifepristone in Hypercortisolism: Mechanism, Metabolic Benefits, and Management Challenges

Auchus and DeFronzo use the CATALYST trial to illustrate that both tumor-related and non-neoplastic hypercortisolism are common in refractory diabetes and respond to glucocorticoid receptor blockade, redefining “pseudo-Cushing” as a clinically important disease state.

Non-Neoplastic Hypercortisolism, CATALYST Data, and Expanding the Concept of Cushing Syndrome

Auchus and DeFronzo describe the underuse of hypercortisolism screening in primary care and outline a straightforward, clinically pragmatic approach to the overnight 1-mg dexamethasone suppression test and subsequent workup.

Screening in Primary Care: When and How to Use the Overnight Dexamethasone Suppression Test

In this introductory segment, Richard Auchus, MD, and Ralph DeFronzo, MD, frame hypercortisolism as an underrecognized driver of difficult-to-control type 2 diabetes, hypertension, and osteoporosis, challenging the traditional view of Cushing syndrome as a rare disorder.

Rethinking “Rare” Cushing Syndrome: Hypercortisolism in Difficult-to-Control Diabetes

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Healthcare professionals discuss individualized approaches to second-line therapy for liver disease, considering patient age, fibrosis, and insurance challenges.

How Special Populations and Disease Risk Impact Treatment Assessment in PBC

Experts discuss first-line treatments for Primary Biliary Cholangitis, emphasizing the importance of monitoring and patient compliance for effective management.

Experts Review the First- and Second-Line Treatment Options for PBC

Examine adherence challenges, specialty pharmacy support, and emerging precision medicine approaches in pediatric atopic dermatitis and psoriasis.


Latest News

Caregiver Perceptions Highlight Gaps in Pediatric Asthma Specialist Access

Apple Watch Hypertension Notifications May Give False Reassurance, With Adam Bress, PharmD, MS

Statins and Improved Long-Term Liver Outcomes in PBC, With Jonggi Choi, MD, PhD

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

FDA Accepts NDA, Grants Priority Review for Oveporexton to Treat Narcolepsy Type 1